Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

DOI Web Site 被引用文献5件
  • Kathryn M. Hastie
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Haoyang Li
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Daniel Bedinger
    Carterra, 825 N. 300 W. Ste C309, Salt Lake City, UT 84103, USA.
  • Sharon L. Schendel
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • S. Moses Dennison
    Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Kan Li
    Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Vamseedhar Rayaprolu
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Xiaoying Yu
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Colin Mann
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Michelle Zandonatti
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Ruben Diaz Avalos
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Dawid Zyla
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Tierra Buck
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Sean Hui
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Kelly Shaffer
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Chitra Hariharan
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Jieyun Yin
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Eduardo Olmedillas
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Adrian Enriquez
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Diptiben Parekh
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Milite Abraha
    Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Elizabeth Feeney
    Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Gillian Q. Horn
    Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Yoann Aldon
    Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, Netherlands.
  • Hanif Ali
    Quadrucept Bio, Ltd., Cambridge CB23 6DW, UK.
  • Sanja Aracic
    Myrio Therapeutics Pty, Ltd., 1 Dalmore Drive, Scoresby, VIC 3179, Australia.
  • Ronald R. Cobb
    National Resilience, Inc., 13200 NW Nano Ct., Alachua, FL 32615, USA.
  • Ross S. Federman
    Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Joseph M. Fernandez
    Activemotif, Inc., 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008, USA.
  • Jacob Glanville
    Centivax, Inc., 201 Gateway Blvd., Floor 1, South San Francisco, CA 94080, USA.
  • Robin Green
    Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Gevorg Grigoryan
    Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Ana G. Lujan Hernandez
    Twist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA.
  • David D. Ho
    Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, 701 West 168th St., HHSC 1102, New York, NY 10032, USA.
  • Kuan-Ying A. Huang
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Chang Gung Memorial Hospital and Research Center for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan.
  • John Ingraham
    Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Weidong Jiang
    Shanghai Henlius Biotech, Inc., 9/F, Innov Tower, Zone A, no. 1801 Hongmei Road, Xuhui District, Shanghai, China.
  • Paul Kellam
    Kymab, Ltd., The Bennet Building, Babraham Research Campus, Cambridge CB22 3AT, UK.
  • Cheolmin Kim
    Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Minsoo Kim
    Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Hyeong Mi Kim
    Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Chao Kong
    Sanyou Biopharmaceuticals Co., Ltd., no. 188 Xinjunhuan Road, Building 6B-C, 3rd Floor, Minhang District, Shanghai 201114, China.
  • Shelly J. Krebs
    Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
  • Fei Lan
    Activemotif, Inc., 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008, USA.
  • Guojun Lang
    Sanyou Biopharmaceuticals Co., Ltd., no. 188 Xinjunhuan Road, Building 6B-C, 3rd Floor, Minhang District, Shanghai 201114, China.
  • Sooyoung Lee
    Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Cheuk Lun Leung
    Generate Biomedicines, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.
  • Junli Liu
    Shanghai Henlius Biotech, Inc., 9/F, Innov Tower, Zone A, no. 1801 Hongmei Road, Xuhui District, Shanghai, China.
  • Yanan Lu
    Activemotif, Inc., 1914 Palomar Oaks Way, Suite 150, Carlsbad, CA 92008, USA.
  • Anna MacCamy
    Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA, USA.
  • Andrew T. McGuire
    Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA, USA.
  • Anne L. Palser
    Kymab, Ltd., The Bennet Building, Babraham Research Campus, Cambridge CB22 3AT, UK.
  • Terence H. Rabbitts
    Quadrucept Bio, Ltd., Cambridge CB23 6DW, UK.
  • Zahra Rikhtegaran Tehrani
    Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA.
  • Mohammad M. Sajadi
    Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA.
  • Rogier W. Sanders
    Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, Netherlands.
  • Aaron K. Sato
    Twist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA.
  • Liang Schweizer
    HiFiBiO, Inc., 237 Putnam Avenue, Cambridge, MA 02139, USA.
  • Jimin Seo
    Celltrion, Inc., Department of Research and Development, 23 Academy-ro Yeonsu-gu Incheon, Republic of Korea.
  • Bingqing Shen
    HiFiBiO, Inc., 237 Putnam Avenue, Cambridge, MA 02139, USA.
  • Jonne L. Snitselaar
    Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, Netherlands.
  • Leonidas Stamatatos
    Fred Hutchinson Cancer Research Center, Vaccines and Infectious Diseases Division, Seattle, WA, USA.
  • Yongcong Tan
    Sanyou Biopharmaceuticals Co., Ltd., no. 188 Xinjunhuan Road, Building 6B-C, 3rd Floor, Minhang District, Shanghai 201114, China.
  • Milan T. Tomic
    National Resilience, Inc., 2061 Challenger Dr., Alameda, CA 94501, USA.
  • Marit J. van Gils
    Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, Netherlands.
  • Sawsan Youssef
    Centivax, Inc., 201 Gateway Blvd., Floor 1, South San Francisco, CA 94080, USA.
  • Jian Yu
    Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, 701 West 168th St., HHSC 1102, New York, NY 10032, USA.
  • Tom Z. Yuan
    Twist Bioscience, 681 Gateway Blvd., South San Francisco, CA 94080, USA.
  • Qian Zhang
    HiFiBiO, Inc., 237 Putnam Avenue, Cambridge, MA 02139, USA.
  • Bjoern Peters
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.
  • Georgia D. Tomaras
    Center for Human Systems Immunology, Departments of Surgery, Immunology, and Molecular Genetics and Microbiology and Duke Human Vaccine Institute, Duke University, Durham, NC 27701, USA.
  • Timothy Germann
    Carterra, 825 N. 300 W. Ste C309, Salt Lake City, UT 84103, USA.
  • Erica Ollmann Saphire
    Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA.

書誌事項

公開日
2021-10-22
DOI
  • 10.1126/science.abh2315
公開者
American Association for the Advancement of Science (AAAS)

この論文をさがす

説明

<jats:title>Community of antibodies against COVID-19</jats:title> <jats:p> The severe acute respiratory syndrome coronavirus 2 spike protein is the basis of many vaccines and is a primary target of neutralizing antibodies after COVID-19 infection. The Coronavirus Immunotherapeutic Consortium (CoVIC), comprising 56 partners across the world, has analyzed a panel of 269 monoclonal antibodies (mAbs) and, on the basis of competition profiles, sorted 186 mAbs that target the receptor binding domain into seven communities. Hastie <jats:italic>et al</jats:italic> . went on to structurally analyze representative antibody binding and used pseudovirus neutralization assays to study the effect of spike mutations on antibody function, including the combinations of mutations found in certain variants of concern. These results are important to guide both treatment and prevention efforts. —VV </jats:p>

収録刊行物

  • Science

    Science 374 (6566), 472-478, 2021-10-22

    American Association for the Advancement of Science (AAAS)

被引用文献 (5)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ